Despite Recent Setbacks, Merck's CV Pipeline Is Strong
This article was originally published in The Pink Sheet Daily
Executive Summary
The Big Pharma reports better than expected first quarter revenues and discusses what is coming in R&D and the cardiovascular pipeline.